#BEGIN_DRUGCARD DB00848

# AHFS_Codes:
Not Available

# ATC_Codes:
P02CE01

# Absorption:
Levamisole is rapidly absorbed (2 hours) from the gastrointestinal tract.

# Biotransformation:
Primarily hepatic (extensive) with both active and inactive metabolites.

# Brand_Mixtures:
Not Available

# Brand_Names:
Ergamisol
Ketrax
Lepuron
Nilverm base
Tetramisol
Tetramisole
Tramisol
Vermisol 150
Wormicid

# CAS_Registry_Number:
14769-73-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H12N2S

# Chemical_IUPAC_Name:
(6S)-6-phenyl-2H,3H,5H,6H-imidazo[2,1-b][1,3]thiazole

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
645699

# Description:
An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Adjuvants, Immunologic
Antinematodal Agents
Antirheumatic Agents

# Drug_Interactions:
Acenocoumarol	Levamisole may increase the anticoagulant effect of acenocoumarol.
Anisindione	Levamisole may increase the anticoagulant effect of anisindione.
Dicumarol	Levamisole may increase the anticoagulant effect of dicumarol.
Warfarin	Levamisole may increase the anticoagulant effect of warfarin.

# Drug_Reference:
1675705	Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet. 1991 Jun 29;337(8757):1555-7.
6169	Van Belle H: Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem. 1976 Jul;22(7):972-6.
6203228	Grishchenko SV, Lavrukhina LA, Ketiladze ES, Krylov VF, Ershov FI: [Results of combined therapy using levamisole for patients with influenza complicated by pneumonia] Vopr Virusol. 1984 Mar-Apr;29(2):175-9.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.84

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
210 mg/mL

# Food_Interactions:
Take on an empty stomach.

# GenBank_ID:
Not Available

# Generic_Name:
Levamisole

# HET_ID:
Not Available

# Half_Life:
4.4-5.6 hours (biphasic)

# InChI_Identifier:
InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1

# InChI_Key:
InChIKey=HLFSDGLLUJUHTE-SNVBAGLBSA-N

# Indication:
For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.
Levamisole was originally used as an antihelminthic to treat worm infestations in both humans and animals.

# KEGG_Compound_ID:
C07070

# KEGG_Drug_ID:
D08114

# LIMS_Drug_ID:
848

# Mechanism_Of_Action:
The mechanism of action of levamisole as an antiparasitic agent appears to be tied to its agnositic activity towards the L-subtype nicotinic acetylcholine receptors in nematode muscles. This agonistic action reduces the capacity of the males to control their reproductive muscles and limits their ability to copulate. The mechanism of action of Levamisole as an anticancer drug in combination with fluorouracil is unknown. The effects of levamisole on the immune system are complex. The drug appears to restore depressed immune function rather than to stimulate response to above-normal levels. Levamisole can stimulate formation of antibodies to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis and chemotaxis, and increase neutrophil mobility, adherence, and chemotaxis.

# Melting_Point:
264-265 Â°C

# Molecular_Weight_Avg:
204.291

# Molecular_Weight_Mono:
204.072119084

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450205

# Pharmacology:
Levamisole is a synthetic imidazothiazole derivative that has been widely used in treatment of worm infestations in both humans and animals. As an anthelmintic, it probably works by targeting the nematode nicotinergic acetylcholine receptor. As an immunomodulator, it appears that Levamisole is an immunostimulant which has been shown to increase NK cells and activated T-cells in patients receiving this adjuvantly along with 5FU for Stage III colon cancer.

# Predicted_LogP_Hydrophobicity:
2.2

# Predicted_LogS:
-2.1

# Predicted_Water_Solubility:
1.44e+00 g/l

# Primary_Accession_No:
DB00848

# Protein_Binding:
20-25%

# PubChem_Compound_ID:
26879

# PubChem_Substance_ID:
46509052

# RxList_Link:
http://www.rxlist.com/cgi/generic3/levamisole.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01067

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
L-Tetramisole
Levamisol [INN-Spanish]
Levamisole hydrochloride
Levamisolum [INN-Latin]
Phenyl imidothiazole
dl-Tetramisol
dl-Tetramisole

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> = 40 mg/kg (Pigs, subcutaneous); LD<sub>50</sub> = 180 mg/kg (rat, oral)

# Update_Date:
2013-02-08 16:19:41 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Levamisole

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell junction, synapse, postsynaptic cell membrane

# Drug_Target_1_Chromosome_Location:
1

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15280391	Culetto E, Baylis HA, Richmond JE, Jones AK, Fleming JT, Squire MD, Lewis JA, Sattelle DB: The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J Biol Chem. 2004 Oct 8;279(41):42476-83. Epub 2004 Jul 27.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17314321	Rayes D, Flamini M, Hernando G, Bouzat C: Activation of single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol Pharmacol. 2007 May;71(5):1407-15. Epub 2007 Feb 21.
17629760	Parker S, Peterkin HS, Baylis HA: Muscular dystrophy associated mutations in caveolin-1 induce neurotransmission and locomotion defects in Caenorhabditis elegans. Invert Neurosci. 2007 Sep;7(3):157-64. Epub 2007 Jul 13.
19668355	Hu Y, Xiao SH, Aroian RV: The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist. PLoS Negl Trop Dis. 2009 Aug 11;3(8):e499.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M86383

# Drug_Target_1_GenBank_ID_Protein:
177898

# Drug_Target_1_GeneCard_ID:
CHRNA3

# Drug_Target_1_Gene_Name:
CHRNA3

# Drug_Target_1_Gene_Sequence:
>1509 bp
ATGGCTCTGGCCGTCTCGCTGCCCCTGGCCTGTCGCGCGCGGCTGCTGCTGCTGCTGCTG
TCTCTGCTGCCAGTGGCCAGGGCCTCAGAGGCTGAGCACCGTCTATTTGAGCGGCTGTTT
GAAGATTACAATGAGATCATCCGGCCTGTAGCCAACGTGTCTGACCCAGTCATCATCCAT
TTCGAGGTGTCCATGTCTCAGCTGGTGAAGGTGGATGAAGTAAACCAGATCATGGAGACC
AACCTGTGGCTCAAGCAAATCTGGAATGACTACAAGCTGAAGTGGAACCCCTCTGGCTAT
GGTGGGGCAGAGTTCATGCGTGTCCCTGCACAGAAGATCTGGAAGCCAGACATTGTGCTG
TATAACAATGCTGTTGGGGATTTCCAGGTGACGACCAAGACCAAAGCCTTACTCAAGTAC
ACTGGGGAGGTGACTTGGATACCTCCGGCCATCTTTAAGAGCTCCTGTAAAATCGACGTG
ACCTACTTCCCGTTTGATTACCAAAACTGTACCATGAAGTTCGGTTCCTGGTCCTACGAT
AAGGCGAAAATCGATCTGGTCCTGATCGGCTCTTCCATGAACCTCAAGGACTATTGGGAG
AGCGGCGAGTGGGCCATCATCAAAGCCCCAGGCTACAAACACGACATCAAGTACAACTGC
TGCGAGGAGATCTACCCCGACATCACATACTCGCTGTACAGTCGGCGCCTGCCCTTGTTC
TACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTTCCTCACTGTGCTCGTCTTC
TACCTGCCCTCCGACTGCGGTGAGAAGGTGACCCTGTGCATTTCTGTCCTCCTCTCCCTG
ACGGTGTTTCTCCTGGTGATCACTGAGACCATCCCTTCCACCTCGCTGGTCATCCCCCTG
ATTGGAGAGTACCTCCTGTTCACCATGATTTTTGTAACCTTGTCCATCGTCATCACCGTC
TTCGTGCTCAACGTGCACTACAGAACCCCGACGACACACACAATGCCCTCATGGGTGAAG
ACTGTATTCTTGAACCTGCTCCCCAGGGTCATGTTCATGACCAGGCCAACAAGCAACGAG
GGCAACGCTCAGAAGCCGAGGCCCCTCTACGGTGCCGAGCTCTCAAATCTGAATTGCTTC
AGCCGCGCAGAGTCCAAAGGCTGCAAGGAGGGCTACCCCTGCCAGGACGGGATGTGTGGT
TACTGCCACCACCGCAGGATAAAAATCTCCAATTTCAGTGCTAACCTCACGAGAAGCTCT
AGTTCTGAATCTGTTGATGCTGTGGTGTCCCTCTCTGCTTTGTCACCAGAAATCAAAGAA
GCCATCCAAAGTGTCAAGTATATTGCTGAAAATATGAAAGCACAAAATGAAGCCAAAGAG
ATTCAAGATGATTGGAAGTATGTTGCCATGGTGATTGATCGTATTTTTCTGTGGGTTTTC
ACCCTGGTGTGCATTCTAGGGACAGCAGGATTGTTTCTGCAACCCCTGATGGCCAGGGAA
GATGCATAA

# Drug_Target_1_General_Function:
Involved in acetylcholine receptor activity

# Drug_Target_1_General_References:
11450844	Lev-Lehman E, Bercovich D, Xu W, Stockton DW, Beaudet AL: Characterization of the human beta4 nAChR gene and polymorphisms in CHRNA3 and CHRNB4. J Hum Genet. 2001;46(7):362-6.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16572171	Zody MC, Garber M, Sharpe T, Young SK, Rowen L, O'Neill K, Whittaker CA, Kamal M, Chang JL, Cuomo CA, Dewar K, FitzGerald MG, Kodira CD, Madan A, Qin S, Yang X, Abbasi N, Abouelleil A, Arachchi HM, Baradarani L, Birditt B, Bloom S, Bloom T, Borowsky ML, Burke J, Butler J, Cook A, DeArellano K, DeCaprio D, Dorris L 3rd, Dors M, Eichler EE, Engels R, Fahey J, Fleetwood P, Friedman C, Gearin G, Hall JL, Hensley G, Johnson E, Jones C, Kamat A, Kaur A, Locke DP, Madan A, Munson G, Jaffe DB, Lui A, Macdonald P, Mauceli E, Naylor JW, Nesbitt R, Nicol R, O'Leary SB, Ratcliffe A, Rounsley S, She X, Sneddon KM, Stewart S, Sougnez C, Stone SM, Topham K, Vincent D, Wang S, Zimmer AR, Birren BW, Hood L, Lander ES, Nusbaum C: Analysis of the DNA sequence and duplication history of human chromosome 15. Nature. 2006 Mar 30;440(7084):671-5.
1989896	Mihovilovic M, Roses AD: Expression of mRNAs in human thymus coding for the alpha 3 subunit of a neuronal acetylcholine receptor. Exp Neurol. 1991 Feb;111(2):175-80.
2336208	Fornasari D, Chini B, Tarroni P, Clementi F: Molecular cloning of human neuronal nicotinic receptor alpha 3-subunit. Neurosci Lett. 1990 Apr 6;111(3):351-6.
8906617	Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM: Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 1996 Fall;7(3):217-28.
9009220	Groot Kormelink PJ, Luyten WH: Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32. FEBS Lett. 1997 Jan 6;400(3):309-14.
9921897	Rempel N, Heyers S, Engels H, Sleegers E, Steinlein OK: The structures of the human neuronal nicotinic acetylcholine receptor beta2- and alpha3-subunit genes (CHRNB2 and CHRNA3). Hum Genet. 1998 Dec;103(6):645-53.

# Drug_Target_1_HGNC_ID:
GNC:1957

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6079

# Drug_Target_1_Locus:
15q24

# Drug_Target_1_Molecular_Weight:
57479.5

# Drug_Target_1_Name:
Neuronal acetylcholine receptor subunit alpha-3

# Drug_Target_1_Number_of_Residues:
505

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Nicotine Pathway	SMP00431

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Neuronal acetylcholine receptor subunit alpha-3
MGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEIIRPVANVSDPV
IIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPD
IVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSW
SYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRL
PLFYTINLIIPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLV
IPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTTHTMPSWVKTVFLNLLPRVMFMTRPT
SNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGMCGYCHHRRIKISNFSANLT
RSSSSESVDAVLSLSALSPEIKEAIQSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFL
WVFTLVCILGTAGLFLQPLMAREDA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-31

# Drug_Target_1_Specific_Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

# Drug_Target_1_SwissProt_ID:
P32297

# Drug_Target_1_SwissProt_Name:
ACHA3_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.40

# Drug_Target_1_Transmembrane_Regions:
241-265
273-291
307-328
478-497

# Drug_Target_2_Cellular_Location:
Cell membrane
GPI-anchor
lipid-anchor

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10951365	Chang YL, Stanford CM, Keller JC: Calcium and phosphate supplementation promotes bone cell mineralization: implications for hydroxyapatite (HA)-enhanced bone formation. J Biomed Mater Res. 2000 Nov;52(2):270-8.
11304750	Funk CJ: Alkaline phosphatase activity in whitefly salivary glands and saliva. Arch Insect Biochem Physiol. 2001 Apr;46(4):165-74.
11403767	de Aguiar Matos JA, Borges FP, Tasca T, Bogo MR, De Carli GA, da Graca Fauth M, Dias RD, Bonan CD: Characterisation of an ATP diphosphohydrolase (Apyrase, EC 3.6.1.5) activity in Trichomonas vaginalis. Int J Parasitol. 2001 Jun;31(8):770-5.
11850443	McDougall K, Plumb C, King WA, Hahnel A: Inhibitor profiles of alkaline phosphatases in bovine preattachment embryos and adult tissues. J Histochem Cytochem. 2002 Mar;50(3):415-22.
12615144	Soory M, Suchak A: Effects of alkaline phosphatase and its inhibitor levamisole on the modulation of androgen metabolism by nicotine and minocycline in human gingival and oral periosteal fibroblasts. Arch Oral Biol. 2003 Jan;48(1):69-76.
18719742	Mota A, Silva P, Neves D, Lemos C, Calhau C, Torres D, Martel F, Fraga H, Ribeiro L, Alcada MN, Pinho MJ, Negrao MR, Pedrosa R, Guerreiro S, Guimaraes JT, Azevedo I, Martins MJ: Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ALPPL2

# Drug_Target_2_GenBank_ID_Gene:
J03252

# Drug_Target_2_GenBank_ID_Protein:
178428

# Drug_Target_2_GeneCard_ID:
ALPPL2

# Drug_Target_2_Gene_Name:
ALPPL2

# Drug_Target_2_Gene_Sequence:
>1599 bp
ATGCAGGGGCCCTGGGTGCTGCTCCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATC
ATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCCAGGCAGCCGAGGCCCTGGGT
GCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATGTTCCTGGGT
GACGGGATGGGGGTGTCTACGGTGACAGCTGCCAGGATCCTAAAAGGGCAGAAGAAGGAC
AAACTGGGGCCTGAGACCTTCCTGGCCATGGACCGCTTCCCGTACGTGGCTCTGTCCAAG
ACATACAGTGTAGACAAGCATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGC
GGGGTCAAGGGCAACTTCCAGACCATTGGCTTGAGTGCAGCCGCCCGCTTTAACCAGTGC
AACACGACACGCGGCAACGAGGTCATCTCCGTGGTGAATCGGGCCAAGAAAGCAGGAAAG
TCAGTGGGAGTGGTAACCACCACACGGGTGCAGCATGCCTCGCCAGCCGGCACCTACGCC
CACACGGTGAACCGCAACTGGTACTCGGATGCCGACGTGCCTGCCTCGGCCCGCCAGGAG
GGGTGCCAGGACATCGCCACGCAGCTCATCTCCAACATGGACATTGATGTGATCCTAGGT
GGAGGCCGAAAGTACATGTTTCCCATGGGGACCCCAGACCCTGAGTACCCAGATGACTAC
AGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCAC
CAGGGTGCCCGGTACGTGTGGAACCGCACTGAGCTCCTGCAGGCTTCCCTGGACCCGTCT
GTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAATACGAGATCCACCGAGAC
TCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCTCCTGCTGAGCAGG
AACCCCCGCGGCTTCTTCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATCATGAA
AGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGAGAGGGCG
GGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTC
TTCTCCTTCGGAGGCTACCCCCTGCGAGGGAGCTCCATCTTCGGGCTGGCCCCTGGCAAG
GCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTC
AAGGACGGCGCCCGGCCGGATGTTACGGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAG
CAGTCAGCAGTGCCCCTGGACGGAGAGACCCACGCAGGCGAGGACGTGGCGGTGTTCGCG
CGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTC
ATGGCCTTCGCCGCCTGCCTGGAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGC
ACCACCGACGCCGCGCACCCGGGGCCGTCCGTGGTCCCCGCGTTGCTTCCTCTGCTGGCA
GGGACCTTGCTGCTGCTGGGGACGGCCACTGCTCCCTGA

# Drug_Target_2_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_2_General_References:
2162249	Lowe ME, Strauss AW: Expression of a Nagao-type, phosphatidylinositol-glycan anchored alkaline phosphatase in human choriocarcinomas. Cancer Res. 1990 Jul 1;50(13):3956-62.
2297757	Gum JR, Hicks JW, Sack TL, Kim YS: Molecular cloning of complementary DNAs encoding alkaline phosphatase in human colon cancer cells. Cancer Res. 1990 Feb 15;50(4):1085-91.
2745460	Watanabe S, Watanabe T, Li WB, Soong BW, Chou JY: Expression of the germ cell alkaline phosphatase gene in human choriocarcinoma cells. J Biol Chem. 1989 Jul 25;264(21):12611-9.
2834730	Millan JL, Manes T: Seminoma-derived Nagao isozyme is encoded by a germ-cell alkaline phosphatase gene. Proc Natl Acad Sci U S A. 1988 May;85(9):3024-8.
3387245	Shen LP, Liu H, Kan YW, Kam W: 5' nucleotide sequence of a putative human placental alkaline phosphatase-like gene. Nucleic Acids Res. 1988 Jun 24;16(12):5694.

# Drug_Target_2_HGNC_ID:
HGNC:441

# Drug_Target_2_HPRD_ID:
01380

# Drug_Target_2_ID:
1075

# Drug_Target_2_Locus:
2q37

# Drug_Target_2_Molecular_Weight:
57378

# Drug_Target_2_Name:
Alkaline phosphatase, placental-like

# Drug_Target_2_Number_of_Residues:
532

# Drug_Target_2_PDB_ID:
1EW2

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00245	Alk_phosphatase

# Drug_Target_2_Protein_Sequence:
>Alkaline phosphatase, placental-like precursor
MQGPWVLLLLGLRLQLSLGIIPVEEENPDFWNRQAAEALGAAKKLQPAQTAAKNLIIFLG
DGMGVSTVTAARILKGQKKDKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYLC
GVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVGVVTTTRVQHASPAGAYA
HTVNRNWYSDADVPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPDDY
SQGGTRLDGKNLVQEWLAKHQGARYVWNRTELLQASLDPSVTHLMGLFEPGDMKYEIHRD
STLDPSLMEMTEAALLLLSRNPRGFFLFVEGGRIDHGHHESRAYRALTETIMFDDAIERA
GQLTSEEDTLSLVTADHSHVFSFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVL
KDGARPDVTESESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHGVQEQTFIAHV
MAFAACLEPYTACDLAPRAGTTDAAHPGPSVVPALLPLLAGTLLLLGTATAP

# Drug_Target_2_Reaction:
a phosphate monoester + H2O = an alcohol + phosphate

# Drug_Target_2_Signals:
1-19

# Drug_Target_2_Specific_Function:
A phosphate monoester + H(2)O = an alcohol + phosphate

# Drug_Target_2_SwissProt_ID:
P10696

# Drug_Target_2_SwissProt_Name:
PPBN_HUMAN

# Drug_Target_2_Synonyms:
ALP-1
Alkaline phosphatase Nagao isozyme
Alkaline phosphatase, placental-like precursor
EC 3.1.3.1
GCAP
Germ-cell alkaline phosphatase
PLAP-like

# Drug_Target_2_Theoretical_pI:
6.31

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00848
